Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
Mainz Biomed (NASDAQ:MYNZ) has secured significant public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB) for its pancreatic cancer screening test development. The ISB will fund up to 50% of the total project costs through its Innovation and Technology Support Program.
The company is currently in the feasibility phase, collaborating with Crown Bioscience to evaluate a panel of mRNA biomarkers and a machine learning-driven algorithm using clinical blood samples. This non-invasive, blood-based screening test aims to enable earlier detection of pancreatic cancer, potentially improving treatment outcomes.
Mainz Biomed (NASDAQ:MYNZ) ha ottenuto un importante finanziamento pubblico dalla Investitions- und Strukturbank Rheinland-Pfalz (ISB) per lo sviluppo del suo test di screening per il cancro al pancreas. L'ISB finanzierà fino al 50% dei costi totali del progetto attraverso il suo Programma di Supporto all'Innovazione e alla Tecnologia.
L'azienda si trova attualmente nella fase di fattibilità, collaborando con Crown Bioscience per valutare un pannello di biomarcatori mRNA e un algoritmo basato su apprendimento automatico utilizzando campioni di sangue clinici. Questo test di screening non invasivo, basato sul sangue, mira a consentire una diagnosi precoce del cancro al pancreas, migliorando potenzialmente i risultati del trattamento.
Mainz Biomed (NASDAQ:MYNZ) ha asegurado una financiación pública significativa del Investitions- und Strukturbank Rheinland-Pfalz (ISB) para el desarrollo de su prueba de detección del cáncer de páncreas. El ISB financiará hasta el 50% del costo total del proyecto a través de su Programa de Apoyo a la Innovación y Tecnología.
La empresa se encuentra actualmente en la fase de viabilidad, colaborando con Crown Bioscience para evaluar un panel de biomarcadores de ARNm y un algoritmo basado en aprendizaje automático utilizando muestras clínicas de sangre. Esta prueba de detección no invasiva, basada en sangre, tiene como objetivo permitir una detección más temprana del cáncer de páncreas, mejorando potencialmente los resultados del tratamiento.
Mainz Biomed (NASDAQ:MYNZ)는 췌장암 선별 검사 개발을 위해 Rheinland-Pfalz 투자구조은행(ISB)으로부터 상당한 공공 자금을 확보했습니다. ISB는 혁신 및 기술 지원 프로그램을 통해 총 프로젝트 비용의 최대 50%를 지원할 예정입니다.
회사는 현재 타당성 단계에 있으며, Crown Bioscience와 협력하여 임상 혈액 샘플을 사용해 mRNA 바이오마커 패널과 머신러닝 기반 알고리즘을 평가하고 있습니다. 이 비침습적 혈액 기반 선별 검사는 췌장암을 조기에 발견하여 치료 결과를 개선하는 것을 목표로 합니다.
Mainz Biomed (NASDAQ:MYNZ) a obtenu un financement public important de la part de la Investitions- und Strukturbank Rheinland-Pfalz (ISB) pour le développement de son test de dépistage du cancer du pancréas. L'ISB financera jusqu'à 50 % des coûts totaux du projet via son programme de soutien à l'innovation et à la technologie.
L'entreprise est actuellement en phase de faisabilité, en collaboration avec Crown Bioscience pour évaluer un panel de biomarqueurs ARNm et un algorithme basé sur l'apprentissage automatique utilisant des échantillons de sang cliniques. Ce test de dépistage non invasif, basé sur le sang, vise à permettre une détection plus précoce du cancer du pancréas, améliorant potentiellement les résultats du traitement.
Mainz Biomed (NASDAQ:MYNZ) hat bedeutende öffentliche Fördermittel von der Investitions- und Strukturbank Rheinland-Pfalz (ISB) für die Entwicklung seines Screening-Tests für Bauchspeicheldrüsenkrebs erhalten. Die ISB wird bis zu 50 % der gesamten Projektkosten über ihr Innovations- und Technologieunterstützungsprogramm finanzieren.
Das Unternehmen befindet sich derzeit in der Machbarkeitsphase und arbeitet mit Crown Bioscience zusammen, um ein Panel von mRNA-Biomarkern und einen maschinell lernbasierten Algorithmus anhand klinischer Blutproben zu evaluieren. Dieser nicht-invasive, blutbasierte Screening-Test zielt darauf ab, eine frühere Erkennung von Bauchspeicheldrüsenkrebs zu ermöglichen und somit potenziell die Behandlungsergebnisse zu verbessern.
- Secured public funding covering up to 50% of project costs from German state development bank
- Government backing validates scientific and technological merit of the project
- Partnership with Crown Bioscience for clinical sample evaluation
- Development of innovative non-invasive blood-based screening technology
- Project still in early feasibility phase
- No immediate revenue generation potential
- Success of biomarker panel and ML algorithm yet to be proven
Insights
Mainz Biomed's securing of 50% public funding for its pancreatic cancer test strengthens financial position and validates technology potential.
The ISB funding announcement represents a significant non-dilutive capital infusion for Mainz Biomed's pancreatic cancer screening program. While the exact funding amount isn't disclosed, having up to 50% of project costs covered substantially reduces the company's cash burn rate for this development program.
This grant is particularly valuable for three key reasons:
- It provides external validation from government experts who have vetted the scientific approach
- It extends the company's financial runway without diluting existing shareholders
- It accelerates development of a diagnostic for pancreatic cancer, a disease with poor survival rates when detected late
The technology itself targets a critical gap in oncology diagnostics. Pancreatic cancer is notoriously difficult to detect early, with most cases diagnosed at advanced stages when five-year survival rates drop below 10%. A blood-based screening test would represent a significant advancement over current detection methods.
The company is currently in the feasibility phase, evaluating mRNA biomarkers using actual clinical samples in partnership with Crown Bioscience. The incorporation of machine learning algorithms suggests a sophisticated approach to biomarker pattern recognition that could potentially improve diagnostic accuracy over traditional methods.
This project aligns with Mainz's broader strategy of developing a portfolio of non-invasive cancer diagnostics across multiple indications, potentially creating multiple revenue streams if successful in commercialization.
BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB), the development bank of the German federal state of Rheinland-Pfalz.
Under the ISB’s Innovation and Technology Support Program (Innovations- und Technologieförderungsprogramm), the state will fund up to
The award of the public grant underscores the medical and technological relevance of Mainz Biomed’s approach. The project aims to close a critical gap in cancer diagnostics by detecting pancreatic cancer at an earlier, more treatable stage.
“This support from the ISB is a strong vote of confidence in the potential of our technology and the importance of early detection in combating pancreatic cancer,” said Dr. Moritz Eidens, CSO of Mainz Biomed.
The project is currently in the feasibility phase. Together with Crown Bioscience, Mainz Biomed is evaluating the performance of a panel of mRNA biomarkers and a ML-driven algorithm, using real clinical blood samples. This work is part of the Company’s broader pipeline strategy to expand its portfolio of accessible, non-invasive diagnostics across multiple cancer indications.
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
What funding did Mainz Biomed (MYNZ) receive for its pancreatic cancer test?
What is the current development stage of MYNZ's pancreatic cancer screening test?
How does Mainz Biomed's pancreatic cancer screening test work?
Who is partnering with Mainz Biomed on the pancreatic cancer test development?
What is the significance of the ISB funding for MYNZ?
